Drug intelligence / Profile preview

Brivasac-75

Development stage: Unknown
Lead developer: UCB
Modality: Small Molecules
Administration: Oral

Overview

Brivasac-75 is a generic formulation of brivaracetam, an antiepileptic drug developed and marketed by AMSAC Pharma. Brivaracetam is a high-affinity, selective ligand for synaptic vesicle glycoprotein 2A (SV2A), a membrane protein found in neurons that plays a key role in regulating neurotransmitter release. By binding to SV2A, brivaracetam modulates synaptic vesicle exocytosis, thereby stabilizing neuronal excitability and preventing the hyperexcitable firing associated with seizures. Brivasac-75 is formulated as a 75 mg film-coated tablet and is indicated as an adjunctive therapy for the treatment of partial-onset (focal) seizures in patients with epilepsy.

Brand names: BrivasacBrivasac-75Brivasac75Brivasac 75
Other names: brivaracetam

Targets

SV2A (Synaptic vesicle glycoprotein 2A)

Beyond the preview

Go deeper on Brivasac-75.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brivasac-75.

Explore the full profile